Sumitomo Chemical India Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ztd62euyx30a3jzav2v6enj8.pdf

Key Takeaways


The Monsoon Shock: What Hit Q2

Suresh Ramachandran: "H1 FY '27 was one of the most difficult first halves for the Indian agrochemical industry in over a decade. The main reason was the erratic and unpredictable monsoon."

Domestic Resilience, Export Stumble


Specialty Products: The Growth Engine

Suresh Ramachandran: "In the entire world, we are proud to announce that India is the first country to commercially launch this product anywhere in the world."

Category & Product Mix: Where the Pain Was

CategoryTrendCommentary
Insecticides (38% of H1 revenue)▼ Declined 9% in Q2Most affected by weather; farmers skipped spray rounds.
Herbicides (25% of H1 revenue)▼ Declined 6% in Q2Delayed sowing and dry spells reduced consumption.
Fungicides▼ Declined 6% in Q2Lower demand as farmers skipped spray rounds in dry conditions.
Metal Phosphides▲ Grew 13% in Q2Strong performance bucking the broader trend.
Animal Nutrition & Environmental Health▲ Grew 18% in Q2Together grew 18% in Q2; a bright spot outside crop protection.
PGRs▲ Grew 9% in Q2Held broadly flat.

Margins, Costs & Working Capital

Kunal Mittal: "...to maintain our EBITDA margins equal to or more than 20% level; which was one of our objective, which we have implemented over last few years."

Capex, Pipeline & the Semiconductor Question

Kunal Mittal: "Intentions have already made by the both sides, I think made in public also and the MOU was also been signed during SEMICON 2026. However, before a formal communication to the investors and our shareholders and also our stakeholders, I think some more firm level of maturity of the discussions is required."

Good to Great & Management Transition

Suresh Ramachandran: "Our commitment to you is continuity. The strategy, the financial discipline and the farmer-first approach that delivered our results over the last several years remain unchanged. What we are adding is a sharper focus on execution, which we call our Good to Great initiative..."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin floorMaintain EBITDA margins equal to or more than 20%Ongoing
Inventory normalizationBring inventory down to normalized levels through H2H2 FY27
Dahej commercial productionCommercial production to startQ2 FY28
Tarapur expansion (part 1)First part of ₹20 crore capex to add 3–4 productsWithin FY27
Tarapur expansion (part 2)Second part completionBy end of FY28
INDIFLIN (EXCALIA MAX) manufacturingManufacturing in Tarapur to meet India requirementBy end of FY27
Dahej herbicide intermediateCommercialization of specific intermediate projectQ2 FY 2028–29, possibly preponed
New product introductions1 or 2 new specialty molecules every yearOver next 3 to 5 years
Innovation turnover index9% to 10% of revenue from new productsEvery year
Semiconductor announcementMore conclusive understanding and formal announcementNext few months
Good to Great financial goalFinancial objective and goal to be setNext few weeks

Key Metrics

MetricQ2 FY27
Revenue₹907 cr, down 2% YoY
H1 FY27 revenue₹1,971 cr, down 1% YoY
Gross margin40.7%, down 240 bps YoY; improved 149 bps QoQ
EBITDA margin20.5%, down 297 bps YoY
H1 FY27 EBITDA margin21.3% vs 22% last year
Net profit₹157 cr, down 11% YoY
Net profit margin17.3%
H1 FY27 net profit₹372 cr, up 5% YoY; net profit margin 18.9%, improved 96 bps
H1 FY27 EPS₹7.45 vs ₹7.13 last year
Domestic revenue₹774 cr, grew 2% YoY
Exports revenue₹127 cr, declined 23% YoY
H1 branded products share of export revenue41%, up from 34% last year
H1 specialty products share of revenue28% vs 30% last year
Cash and liquid investments~₹2,523 cr as of 30 Sep 2026, up from ₹2,113 cr in Mar 2026
Net cash from operations (H1 FY27)₹447 cr vs ₹435 cr in H1 FY26
Net working capital days76 days as of Sep 2026 vs 55 days in Sep 2025
Inventory days115 days as of Sep 2026 vs 95 days in Sep 2025
Innovation turnover indexHigh single digit, 9% to 10% every year-on-year